For example, an FFA2-Gi selective bias agonist might mainly target adipose tissue and improve insulin resistance, whereas an FFA2-Gq/11 bias agonist might improve the release of anorectic hormones in the intestine and increase insulin release in the pancreas. The gene discussed is INS; the disease is Insulin resistance.